Prise en charge de l’infection à cytomégalovirus symptomatique chez les patients traités par immunosuppresseurs pour une maladie inflammatoire chronique

Conclusion Symptomatic CMV infection evolution is unpredictable and potentially severe in patients with chronic inflammatory diseases receiving immunosuppressive agents. Although there is no data issued from clinical trials, the observation reported in this article and the publications of similar cases in the medical literature indicate that treatment with valganciclovir seems worth to be used in this context. Stopping immunosuppressive therapy does not seem mandatory.